Optimi Health and Psyence Biomedical sign non-binding letter of intent to advance global psilocybin drug development

Optimi Health and Psyence Biomedical sign non-binding letter of intent to advance global psilocybin drug development 
Psyence Biomedical Ltd; by Andrea Mestrovic; 8/13/24 
Optimi Health Corp. ..., a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd., ... a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent (“LOI”). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved use in the Palliative Care context.